Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Drysdale

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Topics in Medicinal Chemistry|August 5, 2008
Medicinal chemistry of Hsp90 inhibitorsMartin J Drysdale, Paul A Brough
Current Topics in Medicinal Chemistry|November 6, 2007
The SeeDs approach: integrating fragments into drug discoveryRoderick E Hubbard, Ben Davis, Ijen Chen, et al.
Current Topics in Medicinal Chemistry|July 18, 2006
Discovery and development of pyrazole-scaffold Hsp90 inhibitorsEdward McDonald, Keith Jones, Paul A Brough, et al.
Current Opinion in Drug Discovery & Development|August 8, 2006
Targeting Hsp90 for the treatment of cancerMartin J Drysdale, Paul A Brough, Andrew Massey, et al.
Progress in Medicinal Chemistry|January 23, 2003
RNA as a drug targetMartin J Drysdale, Georg Lentzen, Natalia Matassova, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2005
3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperonePaul A Brough, Xavier Barril, Mandy Beswick, et al.
Molecular Cancer Therapeutics|July 5, 2006
Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitorsNicola F Smith, Angela Hayes, Karen James, et al.
Oncotarget|October 6, 2015
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug designAndrew J Massey, Stephen Stokes, Helen Browne, et al.
Breast Cancer Research : BCR|April 24, 2008
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsMichael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski, et al.
Molecular Cancer Therapeutics|April 8, 2010
Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800Andrew J Massey, Joseph Schoepfer, Paul A Brough, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Topics in Medicinal Chemistry|August 5, 2008
Medicinal chemistry of Hsp90 inhibitorsMartin J Drysdale, Paul A Brough
Current Topics in Medicinal Chemistry|November 6, 2007
The SeeDs approach: integrating fragments into drug discoveryRoderick E Hubbard, Ben Davis, Ijen Chen, et al.
Current Topics in Medicinal Chemistry|July 18, 2006
Discovery and development of pyrazole-scaffold Hsp90 inhibitorsEdward McDonald, Keith Jones, Paul A Brough, et al.
Current Opinion in Drug Discovery & Development|August 8, 2006
Targeting Hsp90 for the treatment of cancerMartin J Drysdale, Paul A Brough, Andrew Massey, et al.
Progress in Medicinal Chemistry|January 23, 2003
RNA as a drug targetMartin J Drysdale, Georg Lentzen, Natalia Matassova, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2005
3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperonePaul A Brough, Xavier Barril, Mandy Beswick, et al.
Molecular Cancer Therapeutics|July 5, 2006
Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitorsNicola F Smith, Angela Hayes, Karen James, et al.
Oncotarget|October 6, 2015
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug designAndrew J Massey, Stephen Stokes, Helen Browne, et al.
Breast Cancer Research : BCR|April 24, 2008
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsMichael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski, et al.
Molecular Cancer Therapeutics|April 8, 2010
Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800Andrew J Massey, Joseph Schoepfer, Paul A Brough, et al.
Pageof 3